Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Factor VIII Plays a Direct Role in Osteoblast Development

Emily Ann Larson, BS, Jason A Taylor, MD PhD

Blood (2017) 130 (Supplement 1): 3661.

https://doi.org/10.1182/blood.V130.Suppl_1.3661.3661

Published: 2017

Journal Articles

Heparin-Induced Thrombocytopenia Antibody Testing and Its Cost Effectiveness: Taking a Financial HIT

Anusiyanthan Isaac Mariampillai, MD, Josephine Pineda Dela Cruz, MD, Harry Staszewski, MD, Nina D'Abreo, MD

Blood (2016) 128 (22): 2343.

https://doi.org/10.1182/blood.V128.22.2343.2343

Published: 2016

Journal Articles

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Francesco Passamonti, MD, Martin Griesshammer, MD, Michele Cavo, MD, Miklos Egyed, MDPhD Prof., Giulia Benevolo, MD, Timothy Devos, MDPhD, Jeannie Callum, MD, Alessandro M. Vannucchi, MD, Serdar Sivgin, MD, Caroline Bensasson, PhD, Mahmudul Khan, PhD, Nadjat Mounedji, MD, Guray Saydam, MD Prof

Blood (2015) 126 (23): 2807.

https://doi.org/10.1182/blood.V126.23.2807.2807

Published: 2015

Journal Articles

Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder

Theodore E. Warkentin, MD, Paul Andrew Basciano, MD, Richard A. Bernstein, M.D., Ph.D.

Blood (2013) 122 (21): 2328.

https://doi.org/10.1182/blood.V122.21.2328.2328

Published: 2013

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.

Jawed Fareed, PhD, Margaret Prechel, Ph.D., Michelle Kujawski, Ph.D., He Zhu, Ph.D., Jeanine Walenga, Ph.D., Debra Hoppensteadt, Ph.D., Josephine Cunanan, M.D., Renu Saxena, M.D.

Blood (2007) 110 (11): 3206.

https://doi.org/10.1182/blood.V110.11.3206.3206

Published: 2007

Journal Articles

A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.

Resmi Ravindran, PhD, Imran Khan, Ph.D., Robert Gosselin, Ted Wun, M.D, V.V. Krishnan, Ph.D., Paul Luciw, Ph.D., Kim Janatpour, M.D

Blood (2007) 110 (11): 3216.

https://doi.org/10.1182/blood.V110.11.3216.3216

Published: 2007

Journal Articles

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Theodore E. Warkentin, MD, Richard M. Jay, MD, Michael Makris, MD, John G. Kelton, MD

Blood (2006) 108 (11): 1047.

https://doi.org/10.1182/blood.V108.11.1047.1047

Published: 2006

Journal Articles

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Juan I. Luengo, Kevin J. Duffy, Anthony N. Shaw, Evelyne Delorme, Kenneth J. Wiggall, Leslie Giampa, Nannan Liu, Heather Smith, Shin-Shay Tian, Stephen G. Miller, Richard M. Keenan, Jon Rosen, Susan B. Dillon, Peter Lamb, Connie L. Erickson-Miller

Blood (2004) 104 (11): 2910.

https://doi.org/10.1182/blood.V104.11.2910.2910

Published: 2004

NARROW

Factor VIII Plays a Direct Role in Osteoblast Development

Heparin-Induced Thrombocytopenia Antibody Testing and Its Cost Effectiveness: Taking a Financial HIT

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.

A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only